Find in Library

Since the publication of the DCCT in 1993, the type 1 diabetes standard treatment is based in an intensified plan of insulin administration with the aplication of several dosis of combined basal long action insulin and faster or ultrafast insulins before main meals. This model of intensified insulin therapy ,however, does not always achieve goals of good glycemic control and is subject to great limitations since it concomitantly predisposes the patients with this disease to a higher risk of hypoglycemia and especially weight gain and development of metabolic syndrome The coexistence of type 1 diabetes and obesity with features of the classic insulinresistance syndrome (dual diabetes) ,of the type clasically seen in type 2 diabetes,can lead the type 1 diabetic patient with several years of evolution to a heightened risk of cardiometabolic and renal complications.The EDIC study showed that the greater the weight gain in type 1 diabetics,the greater the risk of cardiovascular events.